GM-CSF-based fusion cytokines as ligands for immune modulation

Journal of Immunology

Volumn 186, Issue 10, 2011, Pages 5527-5532

  Williams, Patrick ^a   Galipeau, Jacques ^b  

^a MCGILL UNIVERSITY   (Canada)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; APC PROTEIN; CHEMOKINE RECEPTOR CCR2; CYCLOPHOSPHAMIDE; CYTOKINE; CYTOKINE ANTIBODY; DENDRITIC CELL VACCINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 3; INTERLEUKIN 3 ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; MYELIN BASIC PROTEIN; PEPTIDE DERIVATIVE; PLACEBO; PROTEIN ANTIBODY; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNITY; BETA CHAIN; BREAST CANCER; CANCER IMMUNOTHERAPY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; GAMMA CHAIN; HEMATOPOIESIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SHORT SURVEY; TRANSGENE; TUMOR;

ANIMALS; CHEMOKINES; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOMODULATION; INTERLEUKINS; LIGANDS; MICE; NEOPLASMS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 79956192874     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003699     Document Type: Short Survey

References (67)

1. Iqbal, J., W. G. Sanger, D. E. Horsman, A. Rosenwald, D. L. Pickering, B. Dave, S. Dave, L. Xiao, K. Cao, Q. Zhu, et al. 2004. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am. J. Pathol. 165: 159-166.
2. Rowley, J. D. 1973. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
3. Kurzrock, R., H. M. Kantarjian, B. J. Druker, and M. Talpaz. 2003. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann. Intern. Med. 138: 819-830.
4. Cortez, D., G. Reuther, and A. M. Pendergast. 1997. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15: 2333-2342.
5. Jones, A. T., and H. J. Ziltener. 1993. Enhancement of the biologic effects of interleukin-3 in vivo by anti-interleukin-3 antibodies. Blood 82: 1133-1141.
6. Ortiz-Sánchez, E., G. Helguera, T. R. Daniels, and M. L. Penichet. 2008. Antibody-cytokine fusion proteins: applications in cancer therapy. Expert Opin. Biol. Ther. 8: 609-632.
7. Lu, J., Y. Peng, Z. J. Zheng, J. H. Pan, Y. Zhang, and Y. Bai. 2008. EGF-IL-18 fusion protein as a potential anti-tumor reagent by induction of immune response and apoptosis in cancer cells. Cancer Lett. 260: 187-197.
8. Lu, J. X., Y. Peng, Z. F. Meng, L. Q. Jin, Y. S. Lu, and M. X. Guan. 2005. Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics. Biochem. Biophys. Res. Commun. 334: 157-161.
9. Small, E. J., P. Fratesi, D. M. Reese, G. Strang, R. Laus, M. V. Peshwa, and F. H. Valone. 2000. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18: 3894-3903.
10. Kantoff, P. W., C. S. Higano, N. D. Shore, E. R. Berger, E. J. Small, D. F. Penson, C. H. Redfern, A. C. Ferrari, R. Dreicer, R. B. Sims, et al. 2010. Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363: 411-422.
11. Mannie, M. D., and D. J. Abbott. 2007. A fusion protein consisting of IL-16 and the encephalitogenic peptide of myelin basic protein constitutes an antigen-specific tolerogenic vaccine that inhibits experimental autoimmune encephalomyelitis. J. Immunol. 179: 1458-1465.
12. Ogasawara, H., N. Takeda-Hirokawa, I. Sekigawa, H. Hashimoto, Y. Kaneko, and S. Hirose. 1999. Inhibitory effect of interleukin-16 on interleukin-2 production by CD4+ T cells. Immunology 96: 215-219. (Pubitemid 29064331)
13. Liu, Y., W. W. Cruikshank, T. O'Loughlin, P. O'Reilly, D. M. Center, and H. Kornfeld. 1999. Identification of a CD4 domain required for interleukin-16 binding and lymphocyte activation. J. Biol. Chem. 274: 23387-23395.
14. Blanchfield, J. L., and M. D. Mannie. 2010. A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC. J. Leukoc. Biol. 87: 509-521.
15. O'Shea, J. J., M. Gadina, and R. D. Schreiber. 2002. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 109(Suppl.): S121-S131.
16. Wen, R., D. Wang, C. McKay, K. D. Bunting, J. C. Marine, E. F. Vanin, G. P. Zambetti, S. J. Korsmeyer, J. N. Ihle, and J. L. Cleveland. 2001. Jak3 selectively regulates Bax and Bcl-2 expression to promote T-cell development. Mol. Cell. Biol. 21: 678-689.
17. Kubo, M., T. Hanada, and A. Yoshimura. 2003. Suppressors of cytokine signaling and immunity. Nat. Immunol. 4: 1169-1176.
18. Yoshimura, A., T. Naka, and M. Kubo. 2007. SOCS proteins, cytokine signalling and immune regulation. Nat. Rev. Immunol. 7: 454-465.
19. Hara, T., and A. Miyajima. 1996. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Stem Cells 14: 605-618. (Pubitemid 26404613)
20. Balzac, F., A. M. Belkin, V. E. Koteliansky, Y. V. Balabanov, F. Altruda, L. Silengo, and G. Tarone. 1993. Expression and functional analysis of a cytoplasmic domain variant of the beta 1 integrin subunit. J. Cell Biol. 121: 171-178. (Pubitemid 23097373)
21. Kasper, S., T. Kindler, S. Sonnenschein, F. Breitenbuecher, F. D. Böhmer, C. Huber, and T. Fischer. 2007. Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation. J. Interferon Cytokine Res. 27: 947-959.
22. Kotone-Miyahara, Y., K. Yamashita, K. K. Lee, S. Yonehara, T. Uchiyama, M. Sasada, and A. Takahashi. 2004. Short-term delay of Fas-stimulated apoptosis by GM-CSF as a result of temporary suppression of FADD recruitment in neutrophils: evidence implicating phosphatidylinositol 3-kinase and MEK1-ERK1/2 pathways downstream of classical protein kinase C. J. Leukoc. Biol. 76: 1047-1056.
23. Hamilton, J. A. 2008. Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8: 533-544.
24. Selleri, S., S. Deola, Z. Pos, P. Jin, A. Worschech, S. L. Slezak, C. Rumio, M. C. Panelli, D. Maric, D. F. Stroncek, et al. 2008. GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J. Transl. Med. 6: 17.
25. Jackson, S. H., C. R. Yu, R. M. Mahdi, S. Ebong, and C. E. Egwuagu. 2004. Dendritic cell maturation requires STAT1 and is under feedback regulation by suppressors of cytokine signaling. J. Immunol. 172: 2307-2315.
26. Donahue, R. E., J. Seehra, M. Metzger, D. Lefebvre, B. Rock, S. Carbone, D. G. Nathan, M. Garnick, P. K. Sehgal, D. Laston, et al. 1988. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates. Science 241: 1820-1823.
27. Vadhan-Raj, S., H. E. Broxmeyer, M. Andreeff, J. C. Bandres, E. S. Buescher, R. S. Benjamin, N. E. Papadopoulos, A. Burgess, S. Patel, C. Plager, et al. 1995. In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study. Blood 86: 2098-2105.
28. Curtis, B. M., D. E. Williams, H. E. Broxmeyer, J. Dunn, T. Farrah, E. Jeffery, W. Clevenger, P. deRoos, U. Martin, D. Friend, et al. 1991. Enhanced hematopoietic activity of a human granulocyte/macrophage colony-stimulating factor-interleukin 3 fusion protein. Proc. Natl. Acad. Sci. USA 88: 5809-5813.
29. Izquierdo, M. A., D. Degen, E. Raymond, D. Caron, V. Ortiz, P. Banks, and D. D. Von Hoff. 1996. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin 3 fusion protein, on human tumor colony-forming units taken directly from patients. Clin. Cancer Res. 2: 1713-1716.
30. Vadhan-Raj, S., N. E. Papadopoulos, M. A. Burgess, K. A. Linke, S. R. Patel, C. Hays, A. Arcenas, C. Plager, A. P. Kudelka, W. N. Hittelman, et al. 1994. Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J. Clin. Oncol. 12: 715-724.
31. O'Shaughnessy, J. A., A. Tolcher, D. Riseberg, D. Venzon, J. Zujewski, M. Noone, M. Gossard, D. Danforth, J. Jacobson, V. Chang, et al. 1996. Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte- macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. Blood 87: 2205-2211.
32. Asao, H., C. Okuyama, S. Kumaki, N. Ishii, S. Tsuchiya, D. Foster, and K. Sugamura. 2001. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167: 1-5. (Pubitemid 32567752)
33. Fehniger, T. A., and M. A. Caligiuri. 2001. Interleukin 15: biology and relevance to human disease. Blood 97: 14-32.
34. Kovanen, P. E., A. Rosenwald, J. Fu, E. M. Hurt, L. T. Lam, J. M. Giltnane, G. Wright, L. M. Staudt, and W. J. Leonard. 2003. Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J. Biol. Chem. 278: 5205-5213.
35. Carson, W. E., T. A. Fehniger, S. Haldar, K. Eckhert, M. J. Lindemann, C. F. Lai, C. M. Croce, H. Baumann, and M. A. Caligiuri. 1997. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99: 937-943.
36. de Totero, D., R. Meazza, M. Capaia, M. Fabbi, B. Azzarone, E. Balleari, M. Gobbi, G. Cutrona, M. Ferrarini, and S. Ferrini. 2008. The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 111: 517-524.
37. Kumano, M., I. Hara, J. Furukawa, S. Oniki, H. Nagai, H. Miyake, and M. Fujisawa. 2007. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma. J. Urol. 178: 1504-1509. (Pubitemid 47368380)
38. Roda, J. M., R. Parihar, A. Lehman, A. Mani, S. Tridandapani, and W. E. Carson III. 2006. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177: 120-129.
39. Li, Y., and C. Yee. 2008. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111: 229-235.
40. Zorn, E., E. A. Nelson, M. Mohseni, F. Porcheray, H. Kim, D. Litsa, R. Bellucci, E. Raderschall, C. Canning, R. J. Soiffer, et al. 2006. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108: 1571-1579. (Pubitemid 44316124)
41. Stagg, J., J. H. Wu, N. Bouganim, and J. Galipeau. 2004. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy. Cancer Res. 64: 8795-8799. (Pubitemid 39665478)
42. Penafuerte, C., N. Bautista-Lopez, M. R. Boulassel, J. P. Routy, and J. Galipeau. 2009. The human ortholog of granulocyte macrophage colony-stimulating factor and interleukin-2 fusion protein induces potent ex vivo natural killer cell activation and maturation. [Published erratum appears in 2010 Cancer Res. 70: 6106.] Cancer Res. 69: 9020-9028.
43. Faisal, M., W. Cumberland, R. Champlin, and J. L. Fahey. 1990. Effect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia. Blood 76: 1580-1585.
44. Rafei, M., J. H. Wu, B. Annabi, L. Lejeune, M. François, and J. Galipeau. 2007. A GMCSF and IL-15 fusokine leads to paradoxical immunosuppression in vivo via asymmetrical JAK/STAT signaling through the IL-15 receptor complex. Blood 109: 2234-2242. (Pubitemid 46348228)
45. Rafei, M., J. Hsieh, S. Zehntner, M. Li, K. Forner, E. Birman, M. N. Boivin, Y. K. Young, C. Perreault, and J. Galipeau. 2009. A granulocyte- macrophage colony-stimulating factor and interleukin-15 fusokine induces a regulatory B cell population with immune suppressive properties. Nat. Med. 15: 1038-1045.
46. Williams, P., M. Rafei, M. Bouchentouf, J. Raven, S. Yuan, J. Cuerquis, K. A. Forner, E. Birman, and J. Galipeau. 2010. A fusion of GMCSF and IL-21 initiates hypersignaling through the IL-21Ralpha chain with immune activating and tumoricidal effects in vivo. Mol. Ther. 18: 1293-1301.
47. Williams, P., M. Bouchentouf, M. Rafei, R. Romieu-Mourez, J. Hsieh, M. N. Boivin, S. Yuan, K. A. Forner, E. Birman, and J. Galipeau. 2010. A dendritic cell population generated by a fusion of GM-CSF and IL-21 induces tumor-antigen-specific immunity. J. Immunol. 185: 7358-7366.
48. Yasukawa, H., M. Ohishi, H. Mori, M. Murakami, T. Chinen, D. Aki, T. Hanada, K. Takeda, S. Akira, M. Hoshijima, et al. 2003. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4: 551-556.
49. Proost, P., I. De Meester, D. Schols, S. Struyf, A. M. Lambeir, A. Wuyts, G. Opdenakker, E. De Clercq, S. Scharpé, and J. Van Damme. 1998. Aminoterminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection. J. Biol. Chem. 273: 7222-7227.
50. Rollins, B. J. 1997. Chemokines. Blood 90: 909-928. (Pubitemid 27314123)
51. Yuen, J. W., L. S. Poon, A. S. Chan, F. W. Yu, R. K. Lo, and Y. H. Wong. 2010. Activation of STAT3 by specific Galpha subunits and multiple Gbetagamma dimers. Int. J. Biochem. Cell Biol. 42: 1052-1059.
52. De Vries, L., B. Zheng, T. Fischer, E. Elenko, and M. G. Farquhar. 2000. The regulator of G protein signaling family. Annu. Rev. Pharmacol. Toxicol. 40: 235-271.
53. Tohgo, A., E. W. Choy, D. Gesty-Palmer, K. L. Pierce, S. Laporte, R. H. Oakley, M. G. Caron, R. J. Lefkowitz, and L. M. Luttrell. 2003. The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J. Biol. Chem. 278: 6258-6267.
54. Ohnishi, H., J. T. Chao, K. K. Lin, H. Lee, and T. M. Chu. 1989. Role of the kidney in metabolic change of interleukin-2. Tumour Biol. 10: 202-214.
55. Rafei, M., J. Hsieh, S. Fortier, M. Li, S. Yuan, E. Birman, K. Forner, M. N. Boivin, K. Doody, M. Tremblay, et al. 2008. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 112: 4991-4998.
56. McQuibban, G. A., J. H. Gong, J. P. Wong, J. L. Wallace, I. Clark-Lewis, and C. M. Overall. 2002. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100: 1160-1167.
57. Huang, D. R., J. Wang, P. Kivisakk, B. J. Rollins, and R. M. Ransohoff. 2001. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 193: 713-726.
58. Jee, Y., W. K. Yoon, Y. Okura, N. Tanuma, and Y. Matsumoto. 2002. Upregulation of monocyte chemotactic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 128: 49-57. (Pubitemid 34722363)
59. Izikson, L., R. S. Klein, I. F. Charo, H. L. Weiner, and A. D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192: 1075-1080.
60. Zhang, J., L. Patel, and K. J. Pienta. 2010. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21: 41-48.
61. Charo, I. F. 1999. CCR2: from cloning to the creation of knockout mice. Chem. Immunol. 72: 30-41.
62. Rafei, M., Y. A. Berchiche, E. Birman, M. N. Boivin, Y. K. Young, J. H. Wu, N. Heveker, and J. Galipeau. 2009. An engineered GM-CSF-CCL2 fusokine is a potent inhibitor of CCR2-driven inflammation as demonstrated in a murine model of inflammatory arthritis. J. Immunol. 183: 1759-1766.
63. Rafei, M., P. M. Campeau, J. H. Wu, E. Birman, K. Forner, M. N. Boivin, and J. Galipeau. 2009. Selective inhibition of CCR2 expressing lymphomyeloid cells in experimental autoimmune encephalomyelitis by a GM-CSF-MCP1 fusokine. J. Immunol. 182: 2620-2627.
64. DeNardo, D. G., J. B. Barreto, P. Andreu, L. Vasquez, D. Tawfik, N. Kolhatkar, and L. M. Coussens. 2009. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91-102.
65. Blanpain, C., I. Migeotte, B. Lee, J. Vakili, B. J. Doranz, C. Govaerts, G. Vassart, R. W. Doms, and M. Parmentier. 1999. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 94: 1899-1905. (Pubitemid 29430405)
66. Edman, L. C., H. Mira, and E. Arenas. 2008. The beta-chemokines CCL2 and CCL7 are two novel differentiation factors for midbrain dopaminergic precursors and neurons. Exp. Cell Res. 314: 2123-2130.
67. Szymczak, W. A., and G. S. Deepe Jr. 2009. The CCL7-CCL2-CCR2 axis regulates IL-4 production in lungs and fungal immunity. J. Immunol. 183: 1964-1974.